0001209191-19-021059.txt : 20190322
0001209191-19-021059.hdr.sgml : 20190322
20190322173727
ACCESSION NUMBER: 0001209191-19-021059
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190320
FILED AS OF DATE: 20190322
DATE AS OF CHANGE: 20190322
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Neff Thomas B
CENTRAL INDEX KEY: 0001623238
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36740
FILM NUMBER: 19700840
MAIL ADDRESS:
STREET 1: C/O FIBROGEN, INC.
STREET 2: 409 ILLINOIS ST.
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: FIBROGEN INC
CENTRAL INDEX KEY: 0000921299
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 409 ILLINOIS STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-978-1200
MAIL ADDRESS:
STREET 1: 409 ILLINOIS STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-03-20
0
0000921299
FIBROGEN INC
FGEN
0001623238
Neff Thomas B
C/O FIBROGEN, INC.
409 ILLINOIS ST.
SAN FRANCISCO
CA
94158
1
1
0
0
Chief Executive Officer
Common Stock
2019-03-20
4
M
0
6834
2.90
A
2596440
D
Common Stock
2019-03-20
4
S
0
11134
55.14
D
2585306
D
Common Stock
2019-03-20
4
S
0
7266
55.83
D
2578040
D
Common Stock
2019-03-20
4
S
0
428
55.09
D
75006
I
By Family Partnership
Common Stock
2019-03-20
4
S
0
990
55.83
D
74016
I
By Family Partnership
Common Stock
2019-03-21
4
M
0
6834
2.90
A
2584874
D
Common Stock
2019-03-21
4
S
0
9642
55.37
D
2575232
D
Common Stock
2019-03-21
4
S
0
8758
55.85
D
2566474
D
Common Stock
2019-03-21
4
S
0
1418
55.83
D
72598
I
By Family Partnership
Common Stock
20000
I
By Spouse
Common Stock
60946
I
See footnote
Stock Option (Right to Buy)
2.90
2019-03-20
4
M
0
6834
0.00
D
2020-06-09
Common Stock
6834
321216
D
Stock Option (Right to Buy)
2.90
2019-03-21
4
M
0
6834
0.00
D
2020-06-09
Common Stock
6834
314382
D
Shares sold pursuant to a 10b5-1 plan.
The shares were sold at prices ranging from $54.48 to $55.47. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares were sold at prices ranging from $55.495 to $56.23. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares were sold at prices ranging from $54.89 to $55.32. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares were sold at prices ranging from $55.59 to $56.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares were sold at prices ranging from $54.65 to $55.64. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares were sold at prices ranging from $55.65 to $56.18. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares were sold at prices ranging from $55.32 to $55.98. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
Fully vested.
/s/ Dorothy Pacini, Attorney-in-fact
2019-03-22